Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30566000 | 1.00 | MAPT (0.50) | MAPTRAB9ASMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL7338729 | 0.90 | ALDH1A1 (0.48) | MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19985874 | 0.86 | MAOB (0.49) | MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL29678473 | 0.84 | MAPT (0.53) | MAPTRAB9ASMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL5663071 | 0.84 | MAPT (0.53) | MAPTRAB9ASMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL10204012 | 0.81 | RAB9A (0.48) | MAPTRAB9ASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL563821 | 0.80 | KMT2A (0.47) | RAB9AKMT2A | |
| SCHEMBL7961062 | 0.80 | PKM (0.39) | KMT2A | |
| SCHEMBL9800366 | 0.79 | TDP1 (0.51) | MAPTRAB9ASMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL3262594 | 0.79 | HPGD (0.49) | MAPTRAB9ASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163044-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-05-22 | — | — | US | disclosed |
| EP-4452979-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023226381-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海英诺富成生物科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20230348419-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| US-20230348419-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2021055705-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-25 | — | — | WO | disclosed |
| US-10806794-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3515902-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2019-07-31 | — | — | EP | disclosed |
| WO-1995024200-A1 | METHOD FOR TREATING 5HT2B RECEPTOR RELATED CONDITIONS | ELI LILLY AND COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994023720-A1 | TETRAHYDRO-BETA-CARBOLINES | ELI LILLY AND COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1994024127-A1 | INDOLE DERIVATIVES AS 5-H1-LIKE AGONISTS FOR USE IN MIGRAINE | PFIZER LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
| EP-0620222-A2 | Tetrahydro-beta-carbolines | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| US-4876267-A | MIGRANES | GLAXO GROUP LIMITED (GB) | 1989-10-24 | — | — | US | disclosed |
| US-4816470-A | Heterocyclic compounds | GLAXO GROUP LIMITED | 1989-03-28 | — | — | US | disclosed |
| EP-0254433-A2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1988-01-27 | — | — | EP | disclosed |
| US-4650810-A | OR INDOLE-5-THIOACETAMIDES | GLAXO GROUP LIMITED (GB) | 1987-03-17 | — | — | US | disclosed |
| US-4252803-A | HYPOTENSIVE AGENTS, ANALGESICS | GLAXO GROUP LIMITED (GB) | 1981-02-24 | — | — | US | disclosed |
| US-4009328-A | Aminoglycoside 66-40C, method for its manufacture, method for its use as an intermediate in the preparation of known antibiotics and novel antibacterials | SCHERING CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348419-A1 | BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT | RECQL, NQO1, BRD4 | MAPT 1301/4885RAB9A 959/4885SMN1; SMN2 3063/4885 |
| US-10806794-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | MAPT 1280/4885RAB9A 2701/4885SMN1; SMN2 3850/4885 |
| US-20250163044-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | MAPT 139/4885RAB9A 2210/4885SMN1; SMN2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.